Meropenem
- Generic Name
- Meropenem
- Brand Names
- Vabomere
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25N3O5S
- CAS Number
- 96036-03-2
- Unique Ingredient Identifier
- YOP6PX0BAO
- Background
Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.
...
- Indication
For use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, vi...
- Associated Conditions
- Bacterial Infections, Complicated Intra-Abdominal Infections (cIAIs), Meningitis, Bacterial, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin infection bacterial
- Associated Therapies
- -
PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)
- Conditions
- Interventions
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 1084
- Registration Number
- NCT03671967
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
🇮🇱Meir Medical Center, Kfar Saba, Israel
🇮🇱Sourasky Medical Center, Tel Aviv, Israel
Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
- Conditions
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Wockhardt
- Target Recruit Count
- 1004
- Registration Number
- NCT03630081
Pharmacokinetics of Meropenem During High-dose CRRT
- First Posted Date
- 2018-04-25
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Medical University of Lublin
- Target Recruit Count
- 19
- Registration Number
- NCT03507751
- Locations
- 🇵🇱
Oddział Kliniczny Anestezjologii i Intensywnej Terapii, Wojewódzki Szpital Specjalistyczny w Olsztynie, Olsztyn, Poland
Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam
- Conditions
- Interventions
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT03485950
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria
- Conditions
- Interventions
- First Posted Date
- 2018-03-26
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- Venus Remedies Limited
- Target Recruit Count
- 230
- Registration Number
- NCT03477422
- Locations
- 🇮🇳
Deenanath Mangeshkar Hospital and Research Centre, Pune, Maharashtra, India
🇮🇳Christian Medical College & Hospital, Ludhiana, Punjab, India
🇮🇳Ajanta Hospital & Research Centre, 765, ABC Complex, Kanpur Road, Alambagh, -, , India., Lucknow, Uttar Pradesh, India
Bolus Versus Continuous Infusion of Meropenem
- Conditions
- Interventions
- First Posted Date
- 2018-03-02
- Last Posted Date
- 2022-12-27
- Lead Sponsor
- Università Vita-Salute San Raffaele
- Target Recruit Count
- 607
- Registration Number
- NCT03452839
- Locations
- 🇭🇷
University Hospital Dubrava, Dubrava, Croatia
🇰🇿Astana Medical University, Kazakhstan, Kazakhstan
🇷🇺Federal Clinical & Research Center for Reanimatology and Rehabilitation, Moscow, Russian Federation
MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)
- Conditions
- Interventions
- First Posted Date
- 2017-07-26
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 134
- Registration Number
- NCT03230838
- Locations
- 🇺🇸
SUNY Upstate Medical University Hospital ( Site 2510), Syracuse, New York, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 2519), Chicago, Illinois, United States
🇺🇸Baylor College Of Medicine ( Site 2515), Houston, Texas, United States
MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)
- Conditions
- Interventions
- First Posted Date
- 2017-07-13
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 94
- Registration Number
- NCT03217136
- Locations
- 🇿🇦
Red Cross War Memorial Children's Hospital ( Site 1902), Cape Town, Western Cape, South Africa
🇲🇾Universiti Kebangsaan Malaya Medical Centre ( Site 1101), Cheras, Johor, Malaysia
🇺🇸Children's Hospital of Orange County ( Site 2502), Orange, California, United States
A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 21
- Registration Number
- NCT03182504
- Locations
- 🇺🇸
Pulmonary Associates Clinical Trials (PACT), Phoenix, Arizona, United States
A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT03174795
- Locations
- 🇺🇸
eStudySite, La Mesa, California, United States
🇭🇺Semmelweis University, First Dept of Medicine, Budapest, Hungary
🇺🇸Jacksonville Center For Clinical Research, Jacksonville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.